Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Nephro Care IPO
Nephro Care India Ltd
₹1,36,000 /1600 sharesMinimum Investment
Nephro Care IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 28 Jun ‘24 - 2 Jul ‘24 | ₹1,36,000 | 1,600 | ₹85 - ₹90 |
| Issue Size | IPO Doc |
|---|---|
| 41.26Cr | RHP PDF |
About Nephro Care
Founded in
2014
Managing director
Dr. Pratim Sengupta
Parent organisation
Nephro Care India Ltd
Strengths & Financials of Nephro Care
Strengths
Risks
The company has developed in-house technology to produce dialysis-ready water from tap water using a portable RO system, which can be installed anywhere near a water supply. This RO system is being commercialised, and several units have been deployed for "Home Dialysis."
Their Telemedicine app allows patients to access telemedicine services via video, phone, or chat. Developed in-house, the app is currently in beta testing. The average monthly consultations through the app in Kolkata increased by 262.38%, from Rs 0.02 crore in fiscal 2022 to Rs 0.07 crore in fiscal 2023 to Rs 0.24 crore in the nine months ending December 31, 2023.
Each clinic operates on a ‘hub-and-spoke’ model, independently equipped with skilled healthcare professionals and advanced infrastructure to meet patients' healthcare needs and ensure their rehabilitation.
The company serves about 900 CKD patients per month. The income generated from healthcare services has increased steadily from Rs 1.82 crore in 2021 to Rs 3.42 crore in 2022, Rs 17.09 crore in 2023, and Rs 19.75 crore in the nine months ending December 31, 2023.
The company recently signed an agreement to lease a 60-bed hospital in Madhyamgram, Kolkata, and is converting it into a 100-bed multi-speciality hospital.
Almost 99% of the company’s revenue came from the flagship Salt Lake clinic for the period ending December 31, 2023, and the years ending March 31, 2023, and March 31, 2022. This heavy reliance on a single clinic means any disruption to its operations or changes in the economic or political environment in West Bengal, especially in Kolkata, could impact its business.
Pricing regulations and related government reforms in the healthcare industry and associated uncertainty may adversely affect the company’s business.
The company faces competition from other healthcare service providers. Any inability to compete effectively could adversely affect its business.
The company depends heavily on the knowledge and experience of the promoter, Dr. Pratim Sengupta. It is crucial for the business that he remains associated with Nephro Care India for its future growth.
Nephro Care Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Nephro Care IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹85 - 90 | ₹2 - 5 Lakh |
| High Networth Individual | ₹85 - 90 | ₹2 - 5 Lakh |
For Nephro Care IPO, eligible investors can apply as Regular.